PCT

PATENT COOPERATION TREATY

WIPO

INTERNATIONAL PRELIMINARY EXAMINATION REPOREC'D 13 APR 2004

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 600208300003	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)					
International application No.	International filing date (day/mor	nth/year)	Priority date (day/month/year)			
PCT/US03/17442	04 June 2003 (04.06.2003)		06 June 2002 (06.06.2002)			
International Patent Classification (IPC)			(2012)			
IPC(7): C07H 21/04; C07K 5/00, 14/00	; C12N 15/63, 15/00 and US Cl.:	435/320.1, 325,	69.6; 514/2, 822; 530/300, 350			
Applicant						
WUN, TZE, CHEIN						
 This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36. This REPORT consists of a total of sheets, including this cover sheet. This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made 						
			nistrative Instructions under the PCT).			
These annexes consist of a total of sheets.						
3. This report contains indica	ations relating to the following i	tems:				
I Basis of the rep	ort					
II Priority						
III Non-establishme	ent of report with regard to nov	elty, inventive	step and industrial applicability			
IV Lack of unity of	finvention					
V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
VI Certain docume	nts cited					
VII Certain defects in the international application						
VIII Certain observations on the international application						
Date of submission of the demand	Date	of completion	of this report			
23 December 2003 (23.12.2003)		bruary 2004 (07.	_			
Name and mailing address of the IPEA/U	JS Aytho	rized office?				
Mail Stop PCT, Attn: IPEA/US Commissioner for Patents	Holly	Costores	paulrence for			
P.O. Box 1450 Alexandria, Virginia 22313-1450	1					
Facsimile No. (703)305-3230	relepr	none No. (703 3	00-0130			

Form PCT/IPEA/409 (cover sheet)(July 1998)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.	
PCT/US03/17442	

I	Bas	is of the report					
1	With	h regard to the elements of the international application:*					
	\boxtimes	the international application as originally filed.					
	\boxtimes	the description:					
		pages 1-30 as originally filed					
		pages NONE , filed with the demand pages NONE , filed with the letter of .					
	∇						
		the claims: pages <u>31-33</u> , as originally filed					
		pages NONE , as amended (together with any statement) under Article 19					
		pages NONE , filed with the demand					
		pages NONE , filed with the letter of					
	\bowtie	the drawings:					
		pages 1-5 , as originally filed pages NONE , filed with the demand					
		pages NONE , filed with the letter of .					
	\boxtimes	the sequence listing part of the description:					
		pages 1-20 , as originally filed					
		pages NONE , filed with the demand					
2	Wit	pages NONE , filed with the letter of h regard to the language, all the elements marked above were available or furnished to this Authority in the					
-	lang	uage in which the international application was filed, unless otherwise indicated under this item.					
	Thes	se elements were available or furnished to this Authority in the following language which is:					
		the language of a translation furnished for the purposes of international search (under Rule23.1(b)).					
		the language of publication of the international application (under Rule 48.3(b)).					
		the language of the translation furnished for the purposes of international preliminary examination(under Rules					
		55.2 and/or 55.3).					
3.	With	n regard to any nucleotide and/or amino acid sequence disclosed in the international application, the national preliminary examination was carried out on the basis of the sequence listing:					
	\boxtimes	contained in the international application in printed form.					
	\boxtimes	filed together with the international application in computer readable form.					
		furnished subsequently to this Authority in written form.					
		furnished subsequently to this Authority in computer readable form.					
		The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the					
		international application as filed has been furnished.					
		The statement that the information recorded in computer readable form is identical to the written sequence listing					
		has been furnished.					
4.		The amendments have resulted in the cancellation of:					
		the description, pages NONE					
		the claims, Nos. NONE					
	_	the drawings, sheets/ fig NONE					
5.		This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**					
* 1	* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in						
ınıs	repor	t as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17). placement sheet containing such amendments must be referred to under item I and annexed to this report.					



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US03/17442

V. Reasoned statement under Rule 66.2(a)(ii) citations and explanations supporting such		rd to novelty, inventive step or industrial applicabil	lity;
1. STATEMENT			
Novelty (N)	Claims	1-23	_YES
	Claims	NONE	_NO
Inventive Step (IS)	Claims	1-23	_YES
	Claims	NONE	_ио
Industrial Applicability (IA)	Claims	1-23	_YES
	Claims	NONE	_NO
annexin V and a KUNITZ protease inhibitor, methods While annexin V and many KUNITZ domain inhibitor teaching or suggestion of making a fusion between the	of making of s were know KUNITZ do	ause the prior art does not teach or fairly suggest fusion proper using the fusion proteins, or DNA encoding such proteins in the prior art as evidenced by DENNIS et al. there is normain inhibitors and annexin V. It have industrial applicability because the subject matter class have industrial applicability because the subject matter class.	s. o

Form PCT/IPEA/409 (Box V) (July 1998)